Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174697 | 0.80 | POLB (0.39) | POLBCYP11B2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2173112 | 0.74 | GRM5 (0.40) | POLBCYP11B2CHRNB4CHRNA3MEN1 | |
| SCHEMBL4630708 | 0.73 | GRM5 (0.46) | POLBMEN1KMT2A | |
| SCHEMBL2378788 | 0.72 | GRM5 (0.43) | LMNA | |
| SCHEMBL27585155 | 0.71 | CYP3A4 (0.59) | POLBCYP11B2CHRNB4CHRNA3LMNA | |
| SCHEMBL27749291 | 0.69 | ALDH1A1 (0.43) | LMNA | |
| SCHEMBL4630595 | 0.69 | GRM5 (0.69) | POLB | |
| SCHEMBL1020277 | 0.69 | GRM5 (0.50) | — | |
| SCHEMBL29050434 | 0.68 | POLB (0.50) | POLBCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL10460756 | 0.68 | KDM4E (0.43) | MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481548-B2 | 2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-4-trifluoromethyl-pyrimidine; metabotropic glutamate (mGluR5) receptor antagonist; analgesic, neurodegenerative diseases; psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders, memory deficits, chronic and acute pain | HOFFMAN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-7973165-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7531529-B2 | Imidazole derivatives | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| CN-100408572-C | imidazole derivatives as glutamate receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | CN | disclosed |
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2008-05-22 | — | — | US | disclosed |
| US-20080103306-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2008-05-01 | — | — | US | disclosed |
| US-7332510-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1636206-B1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | EP | disclosed |
| CN-1802367-A | Imidazole derivatives as glutmate receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-07-12 | — | — | CN | disclosed |
| EP-1636206-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | GRIK5, GRM5, GRIN2B | POLB 4582/4885CYP11B2 925/4885CHRNB4 240/4885 |
| US-20080103306-A1 | IMIDAZOLE DERIVATIVES | GRIK5, GRM5, GRIN2B | POLB 4419/4885CYP11B2 782/4885CHRNB4 259/4885 |
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | POLB 4152/4885CYP11B2 695/4885CHRNB4 263/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | POLB 4425/4885CYP11B2 239/4885CHRNB4 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.